Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) – Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Immunocore in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.26) per share for the year, down from their prior estimate of $0.11. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Immunocore’s Q4 2026 earnings at ($0.22) EPS, FY2028 earnings at $1.81 EPS, FY2029 earnings at $4.15 EPS and FY2030 earnings at $6.98 EPS.
Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. The company had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million.
A number of other equities analysts also recently commented on the company. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. assumed coverage on Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price target on the stock. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research note on Friday, August 7th. Zacks Research cut Immunocore from a “hold” rating to a “strong sell” rating in a research note on Monday. Finally, TD Cowen raised Immunocore to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.00.
Read Our Latest Analysis on IMCR
Immunocore Price Performance
IMCR stock opened at $31.65 on Thursday. Immunocore has a 12-month low of $27.50 and a 12-month high of $40.71. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -48.69 and a beta of 0.82. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The firm’s 50-day moving average price is $31.36 and its two-hundred day moving average price is $31.68.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in IMCR. Engineers Gate Manager LP boosted its holdings in Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after purchasing an additional 46,435 shares during the last quarter. Braidwell LP bought a new stake in Immunocore in the 2nd quarter worth approximately $16,552,000. Eversept Partners LP bought a new stake in Immunocore in the 1st quarter worth approximately $1,183,000. Public Employees Retirement System of Ohio purchased a new stake in Immunocore during the 2nd quarter valued at $2,145,000. Finally, Stempoint Capital LP purchased a new stake in Immunocore during the 1st quarter valued at $1,916,000. 84.50% of the stock is owned by hedge funds and other institutional investors.
Immunocore News Roundup
Investors following IMCR have been watching these news items:
- Positive Sentiment: HC Wainwright kept its Buy rating and $80 price target, well above the roughly $31.65 share price referenced in the reports. It also raised its Q4 2027 EPS estimate to $0.52 from $0.49. HC Wainwright estimate details
- Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the provided report does not specify new findings likely to affect the stock. SITC 2026 presentation
- Negative Sentiment: Zacks Research downgraded Immunocore from Hold to Strong Sell, adding to the cautious analyst outlook. Zacks downgrade report
Immunocore Company Profile
Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.
Read More
- Five stocks we like better than Immunocore
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
